Volume 18, Number 4—April 2012
Dengue in Patients with Central Nervous System Manifestations, Brazil
We investigated the prevalence of dengue in patients with suspected viral meningitis/meningoencephalitis in a dengue-endemic area. Cerebrospinal fluid analysis showed positive results and a 6.74× greater likelihood of identifying positive fluid in patients who died. Our findings support testing patients with neurologic manifestations for the virus in dengue-endemic areas.
Dengue is the most prevalent arboviral infection in humans (1). Since the reintroduction of dengue virus (DENV) into Brazil in the 1980s, >60% of the reported dengue cases in this region of the Western Hemisphere have occurred there (2). As the disease has become more common, unusual clinical signs, some of which involve the central nervous system, have been observed in dengue patients (2–4). We therefore assessed prevalence of dengue neurologic cases from Ceará State, Brazil, a region where dengue is endemic.
We enrolled 183 patients with suspected viral meningitis/meningoencephalitis admitted to São José Hospital of Infectious Disease and 26 deceased patients with suspected fatal meningitis who had been sent to the city of Fortaleza Coroner’s Office. Cerebrospinal fluid (CSF) was collected from all 209 patients. Study inclusion criteria were suspicion of viral meningitis/meningoencephalitis, a CSF cell count <500 cells/mm3, and negative results of culture and microscopic examination for bacteria and fungi. The CSF samples were not contaminated with blood. The study was performed retrospectively and used samples from patients who had been treated for meningitis during 2005–2008, a period during which a dengue epidemic may have occurred in Ceará. This study was approved by the Ethics Committee of São José Hospital of Infectious Disease (protocol no. 005/2009; Certificado de Apresentação para Apreciação Ética [Proof of Application for Ethical Review] 0005.0.042.000–09).
Dengue meningitis was suspected when a patient had fever and symptoms of irritation of the meninges, such as headache and neck stiffness; a diagnosis of dengue meningoencephalitis was established when the patient showed signs of focal involvement of the central nervous system (CNS). A diagnosis of dengue was confirmed with a DENV-positive CSF result by reverse transcription PCR (RT-PCR), nonstructural protein (NS) 1, or IgM against DENV (3,4).
Samples were analyzed by using RT-PCR, ELISA for NS1, and IgM monoclonal antibody and a rapid immunochromatography test for IgG (3–5).Viral RNA for the nested RT-PCR was extracted from 140 µL of the CSF samples by using the QIAamp Viral RNA Mini Kit (QIAGEN, Valencia, CA, USA), following the manufacturer’s protocol, and stored at −80°C until tested. The RT-PCR for DENV was performed on 209 CSF samples, as described (5).
The NS1Ag Pan-E Dengue Early ELISA kit (Panbio Diagnostics, Brisbane, Queensland, Australia) was used to detect the dengue NS1 in 209 CSF specimens in accordance with the manufacturers’ instructions (4). The Dengue IgM Capture ELISA (Panbio Diagnostics) was performed on 209 CSF samples, according to the manufacturer’s instructions. The Panbio Dengue Duo Cassette rapid test was performed, according to the manufacturer’s instructions, with CSF specimens that were positive for DENV in any of the other tests used.
Of 209 CSF samples studied, 8 (3.8%) showed positive results in >1 test: 5 from the group admitted to São José Hospital of Infectious Disease and 3 deceased patients examined at the Fortaleza Coroner’s Office (Table 1). Reviewed literature showed that the etiologic agents of most cases of viral meningitis in Brazil are enterovirus and herpesvirus; cytomegalovirus and dengue viruses are each responsible for 10% (2/20) (6).
DENV as a causal agent for meningitis has been rarely reported, although some cases have been described in the literature. In Jamaica, a study of 401 patients with suspected cases of viral infection of the CNS showed that 54 (13.5%) were positive for dengue; 18 (33.3%) of those patients showed clinical signs of meningitis (7). However, when we included patients in the cohort who were initially suspected of having CNS infection, the frequency of meningitis in this study was 18/401 (4.5%).
An investigation of dengue patients with suspected CNS infection conducted in Vietnam found 4.2% (16/378) of persons positive for DENV; 1 (0.3%) patient had meningitis (3). The frequency of finding dengue virus in patients with suspected cases of meningitis found in this study corroborated what was hypothesized in the literature: neurologic manifestations in patients with DENV have been reported in Ceará, but previous studies based laboratory diagnosis on serum, not on CSF as in our study, which indicated a relationship between dengue and CNS manifestations (8).
Of 5 patients treated at São José Hospital of Infectious Disease (Table 1), 3 recovered, 1 was given a diagnosis of a brain tumor, and 1 died. The patient who died was the only person of 5 with dengue fever who had signs and symptoms of fatal dengue hemorrhagic fever (DHF) (such as intense malaise, dry cough with dyspnea, and abdominal pain) (9). Of the 3 deceased patients (Table 1), only 1 had signs of severe dengue, including myalgia, abdominal pain, asthenia, somnolence, and confusion. Suspected cases of meningitis with other pathologic changes might also be confused with dengue cases with CNS involvement (10). Of 8 dengue patients, 2 had signs and symptoms of dengue infection. In Brazil, meningitis was confirmed for patients with oligosymptomatic dengue infection in the cities of Vitoria and Rio de Janeiro (10,11).
The presence of DENV NS1 antigen (NS1Ag) has been associated with virus replication and viremia with the risk for development of DHF (12). The NS1Ag was detected in 4 of the fatal cases reported here, but because none fulfilled the World Health Organization criteria for DHF, they were considered to have been cases of severe dengue because the patients died (1) (Table 1). Detection of dengue IgM in CSF has shown a high specificity (97%) for diagnosing neurologic dengue and might be associated with the neurovirulence of DENV and its ability to cause encephalitis (13). Prior to the 1996 publication of findings by Lum et al., involvement of the CNS in dengue infection had been thought to be secondary to vasculitis only; direct involvement of the brain by DENV was thought to be unlikely (14),. The literature has reported detection of DENV in the brain and CSF by PCR and virus isolation and detection of NS1 and dengue IgM, providing strong evidence that DENV has neurovirulent properties (3,4,11,13–15). Meningeal lesions, neuronal damage, and evidence of DENV in CSF by RT-PCR and ELISA (NS1/IgM) found in this study are consistent with CNS infection (Table 1).
The prevalence of CNS involvement in patients with dengue infection seems to vary with severity of dengue cases (11). Mortality rates also vary among studies; the reported rate of neurologic dengue was found to be 3.7% (2/54) in a study in Jamaica (7). In another study conducted in Vietnam, no patients with the neurologic form of dengue died (3); our study found a mortality rate of 1.9% (4/209). However, the proportional positivity was higher for the group of patients who died (4/27, 14.8%) than for those who recovered (4/182, 2.2%) (Table 2). The relative risk for identifying DENV-positive CSF in patients who died was 6.74× greater than that for patients who recovered (95% CI 1.79×–25.38×; p<0.0109). No patients had DHF or a concurrent condition to predict deterioration to death, thus suggesting that patients with meningitis/meningoencephalitis and DENV-positive CSF may have higher risk for development of severe forms of dengue infection.
The high risk for death among patients with dengue meningitis/meningoencephalitis in this study supports the need for increased surveillance. Dengue should be suspected in patients with neurologic manifestations in dengue-endemic areas, and appropriate treatment should be given to prevent death.
Dr Araújo is a researcher in the dengue reference laboratory in the State Health Secretariat in Ceara. Her research interest and work for the past 23 years is in dengue viruses in Brazil.
This study was supported by the Brazilian National Research Council, process MCT/CNPq 14/2009, and by the Ceará State Scientific Development Foundation, process FUNCAP 09100097-1.
- World Health Organization. Dengue hemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: The Organization; 1997.
- Nogueira RMR, Araújo JMG, Schatzmayr HG. Dengue virus in Brazil, 1986–2006. Rev Panam Salud Publica. 2007;22:358–63.
- Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, Neurological manifestations of dengue infection. Lancet. 2000;355:1053–9.
- Araújo FMC, Brilhante RSN, Cavalcanti LPG, Rocha MFG, Cordeiro RA, Perdigão ACB, Detection of the dengue non-structural 1 antigen in cerebral spinal fluid samples using a commercially available enzyme-linked immunosorbent assay. J Virol Methods. 2011;177:128–31.
- Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam V. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol. 1992;30:545–51.
- Soares CN, Cabral-Castro MJ, Peralta JM, Freitas MRG, Puccioni-Sohler M. Review of the etiologies of viral meningitis and encephalitis in a dengue endemic region. J Neurol Sci. 2011;303:75–9.
- Jackson ST, Mullings A, Bennett F, Khan C, Gordon-Strachan G, Rhoden T. Dengue infection in patients presenting with neurological manifestations in a dengue endemic population. West Indian Med J. 2008;57:373–6.
- Vasconcelos PFC, Travassos Da Rosa APA, Coelho ICB, Menezes DB, Travassos Da Rosa ES, Rodrigues SG, Involvement of the central nervous system in dengue fever: three serologically confirmed cases from Fortaleza, Ceará, Brazil. Rev Inst Med Trop Sao Paulo. 1998;40:35–9.
- Guzmán MG, Kouri G, Morier L, Soler M, Fernández A. A study of fatal hemorrhagic dengue cases in Cuba, 1981. Bull Pan Am Health Organ. 1984;18:213–20.
- Soares CN, Cabral-Castro MJ, Peralta JM, Freitas MRG, Puccioni-Sohler M. Meningitis determined by oligosymptomatic dengue virus type 3 infection: report of a case. Int J Infect Dis. 2010;14:e150–2.
- Domingues RB, Kuster GW, Onuki-Castro FL, Souza VA, Levi JE, Pannuti CS. Involvement of the central nervous system in patients with dengue virus infection. J Neurol Sci. 2008;267:36–40.
- Duong V, Ly S, Ong S, Cgroeung N, Try PL, Deubel V, Variation of dengue NS1 antigen measured by commercial ELISA kit in various forms of dengue infections and assessment of the association between NS1 level and disease severity. BMC Proceedings. 2011;5:47.
- Soares CN, Faria LC, Puccioni-Sohler M, Peralta JM, Freitas MRG. Dengue infection: neurological manifestations and cerebrospinal fluid (CSF) analysis. J Neurol Sci. 2006;249:19–24.
- Lum LCS, Lam SK, Choy YS, George R, Harun F. Dengue encephalitis: a true entity? Am J Trop Med Hyg. 1996;54:256–9.
- de Araújo JMG, Schatzmayr HG, Filippis AMB, Santos FB, Cardoso MA, Britto C, Retrospective survey of dengue virus infection in fatal cases from an epidemic in Brazil. J Virol Methods. 2009;155:34–8.
- Table 1. Clinical features and virologic findings for 8 patients with meningitis/meningoencephalitis and confirmed cases of dengue, Brazil, 2005–2008
- Table 2. Risk for death among patients with meningitis/meningoencephalitis with DENV+ versus DENV– cerebrospinal fluid test results, Brazil, 2005–2008†
Suggested citation for this article: Araújo, FMC, Nogueira, RMR, Araújo, MS, Perdigão, ACB, Cavalcanti, LPG, Brilhante, RSN, et al. Dengue in patients with central nervous system manifestations, Brazil, Emerg Infect Dis [serial on the Internet]. 2012 Apr [date cited]. http://dx.doi.org/10.3201/eid1804.111522
Please use the form below to submit correspondence to the authors or contact them at the following address:
Fernanda Araújo, Av. Barão de Studart, 2405, 60120-002, Fortaleza, CE, Brazil
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 15, 2012
- Page last updated: March 15, 2012
- Page last reviewed: March 15, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)